Tessa Therapeutics

Recent Finacing

Series A

Recent Raise

$126M

Tessa Therapeutics is a Singapore-based cell-therapy developer of autologous CD30 CAR-T (TT11) and allogeneic EBVST CD30 CAR-T (TT11X), operating a cGMP manufacturing facility and running Phase I–III tumor trials.

Founded 2001

Central Region, Singapore

101-250

Private

tessacell.com

Highlights

Focus Areas

Biotechnology

Health Care

Therapeutics

Recent Investors

Financials

$206M

Total Raised

2

Funding rounds

6

Investors

Team

Upgrade to view the team

See the team members at Tessa Therapeutics.